Low-Dose Valganciclovir for CMV Prophylaxis after Lung Transplantation

Table 3

Zamora study group demographic data.

Age, mean	53.4 ± 4.7
Gender: male/female	50/40
Indications for transplant, 𝑛 (%)
COPD	45 (50)
Alpha 1-antitrypsin deficiency	21 (23.3)
Idiopathic pulmonary fibrosis	8 (8.9)
Cystic fibrosis	12 (13.3)
Primary pulmonary hypertension	4 (5.5)
CMV donor/recipient serostatus, 𝑛 (%)
D+/R−	18 (20)
D+/R+	45 (50)
D−/R+	27 (30)